These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypertrophic Cardiomyopathy: New Concepts and Therapies. Maron BJ; Rowin EJ; Maron MS Annu Rev Med; 2022 Jan; 73():363-375. PubMed ID: 35084989 [TBL] [Abstract][Full Text] [Related]
3. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Maron BJ; Rowin EJ; Maron MS Am J Cardiol; 2024 Feb; 212S():S77-S82. PubMed ID: 38368039 [TBL] [Abstract][Full Text] [Related]
4. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. Maron BJ; Ommen SR; Semsarian C; Spirito P; Olivotto I; Maron MS J Am Coll Cardiol; 2014 Jul; 64(1):83-99. PubMed ID: 24998133 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967 [TBL] [Abstract][Full Text] [Related]
7. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Maron BJ; Rowin EJ; Maron MS Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516 [TBL] [Abstract][Full Text] [Related]
8. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744 [TBL] [Abstract][Full Text] [Related]
9. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Rowin EJ; Hausvater A; Link MS; Abt P; Gionfriddo W; Wang W; Rastegar H; Estes NAM; Maron MS; Maron BJ Circulation; 2017 Dec; 136(25):2420-2436. PubMed ID: 28916640 [TBL] [Abstract][Full Text] [Related]
10. Management of hypertrophic cardiomyopathy in children. Seggewiss H; Rigopoulos A Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624 [TBL] [Abstract][Full Text] [Related]
11. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970 [TBL] [Abstract][Full Text] [Related]
18. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Maron BJ; Maron MS Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314 [TBL] [Abstract][Full Text] [Related]
19. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Maron BJ; Rowin EJ; Casey SA; Haas TS; Chan RH; Udelson JE; Garberich RF; Lesser JR; Appelbaum E; Manning WJ; Maron MS Circulation; 2013 Feb; 127(5):585-93. PubMed ID: 23275385 [TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience. Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]